ESRD (end-stage renal disease)
Clinical trials for ESRD (end-stage renal disease) explained in plain language.
Never miss a new study
Get alerted when new ESRD (end-stage renal disease) trials appear
Sign up with your email to follow new studies for ESRD (end-stage renal disease), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Pig kidney trial offers hope to thousands waiting for transplants
Disease control Recruiting nowThis study is testing whether a kidney from a genetically modified pig can safely work in people with end-stage renal disease who cannot get a human kidney. Up to 50 participants will receive the pig kidney and be followed for at least 24 weeks to check survival, kidney function,…
Matched conditions: ESRD (END-STAGE RENAL DISEASE)
Phase 1/2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New dialysis gadget aims to clean blood better and boost life quality
Disease control Recruiting nowThis study tests a special cartridge (pHA130) added to regular dialysis to remove toxins that standard dialysis misses. One hundred adults with kidney failure on maintenance dialysis will be split into two groups: one gets the new cartridge once a week plus standard dialysis twic…
Matched conditions: ESRD (END-STAGE RENAL DISEASE)
Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Pig kidney transplant trial offers new hope for kidney patients
Disease control Recruiting nowThis study tests a genetically modified pig kidney (called the 10 GE Xenokidney) in 50 adults with end-stage kidney disease who cannot get a human kidney transplant or face a long wait. The goal is to see if the pig kidney works safely and well, improving survival and quality of …
Matched conditions: ESRD (END-STAGE RENAL DISEASE)
Phase 1/2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for dialysis patients: drug AP301 targets dangerous phosphate levels
Disease control Recruiting nowThis phase 3 trial tests whether AP301, a drug taken with meals, can safely lower high blood phosphate in people on kidney dialysis. About 264 participants will receive either AP301 or a low-dose version for 8 weeks, then all get AP301 for 24 weeks. The goal is to see if AP301 he…
Matched conditions: ESRD (END-STAGE RENAL DISEASE)
Phase 3 • Sponsor: Alebund Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC